

The logo for UCSF Health, featuring the letters 'UCSF' in a bold, sans-serif font followed by the word 'Health' in a lighter, sans-serif font.

Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass?

A comparison of 30-day complications using the MBSAQIP data registry

Sandhya B. Kumar MD, Barbara C. Hamilton MD, Soren Jonzzon, Stephanie G. Wood MD, Stanley J. Rogers MD, Jonathan T. Carter MD, Matthew Y.C. Lin MD

University of California, San Francisco
Department of Surgery



Disclosures

Dr. Kumar's fellowship is supported through a grant from the Foundation of Surgical Fellowships

Introduction

- Laparoscopic sleeve gastrectomy (LSG) is now the most popular bariatric procedure in the United States
- Some studies have shown LSG to have fewer overall complications than laparoscopic gastric bypass (LRYGB), but there is lingering concern about a higher leak rate
- The Metabolic and Bariatric Surgery Accreditation and Quality Improvement (MBSAQIP) registry is the largest bariatric-specific dataset available and therefore the best data set to compare LSG and LRYGB in a real-world setting.

1. Peterli R, Borbély Y, Kern B, et al. Early results of the Swiss Multicentre Bypass or Sleeve Study (SM-BOSS): a prospective randomized trial comparing laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass. *Annals of Surgery*. 2013;258(5):690–4.

2. Helmiö M, Victorzon M, Ovaska J, et al. SLEEVEPASS: a randomized prospective multicenter study comparing laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: preliminary results. *Surgical Endoscopy*. 2012;26(9):2521-2526.

3. Young MT, Gebhart A, Phelan MJ, Nguyen NT. Use and Outcomes of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Gastric Bypass: Analysis of the American College of Surgeons NSQIP. *Journal of the American College of Surgeons*. 2015;220(5):880-885.

Objective

- To compare LSG and LRYGB with respect to mortality, serious morbidity, and leak, adjusting for patient characteristics.

Methods

- **Patients:** all patients undergoing bariatric surgery captured by the 2015 MBSAQIP database
- **Inclusion criteria:** all cases of primary LSG or LRYGB identified using CPT codes
- **Exclusion criteria:** revisional operations, open operations
- **Predictors:** Patient demographics and comorbidities

Methods- Outcome variables

Death

Leak = any of

- Leak outcome
- Drain at 30-days
- Organ space infection
- Leak-related readmission
- Leak-related reoperation
- Leak-related intervention

Morbidity = any of

- Deep or organ space infection
- Wound disruption
- Leak
- ICU admission
- Sepsis
- Renal failure
- Transfusion
- Cardiac arrest, myocardial infarction
- Cerebrovascular accident, coma
- Pneumonia, >48h vent, reintubation
- Pulmonary embolism, DVT
- Intervention, reoperation, readmission within 30-days




Statistical Methods

- Missing value imputation
- Partition in to Training (70%) and Testing (30%) sets
- Variable importance using Random Forest Algorithms
- Multivariate Regression Model using forward and backwards stepwise selection, minimizing Aikake Information Criterion (AIC)
- Model Diagnostics – Receiver Operating Characteristic Curves


Patient Characteristic	LSG (n=93,062)	LRGYB (n=41,080)	P-value
Age (years)	44 (35 – 53)	45 (36 – 54)	< 0.001
BMI (kg/m ²)	44 (40 – 49)	45 (41 – 51)	< 0.001
Albumin (mg/dL)	4.1 (3.9 – 4.3)	4.0 (3.8 – 4.2)	< 0.001
Female	79%	79%	0.001
Diabetes			< 0.001
None	77%	65%	
None-insulin dependent	16%	21%	
Insulin dependent	7%	15%	
Hyperlipidemia	23%	30%	< 0.001
Gastroesophageal Reflux	29%	37%	< 0.001
Obstructive Sleep Apnea	35%	43%	< 0.001
COPD	1.7%	2.2%	< 0.001
Oxygen Dependence	0.7%	1.0%	< 0.001
Hypertension	48%	54%	< 0.001
History of MI	1.2%	1.6%	< 0.001
Prior PCI	2.0%	2.5%	< 0.001
Prior Cardiac Surgery	1.2%	1.2%	0.816
Renal Insufficiency	0.7%	0.7%	0.648
Dialysis Dependence	0.3%	0.2%	< 0.001
History of DVT	1.6%	1.8%	< 0.001
History of PE	1.1%	1.2%	0.04
Prior IVC Filter	1.0%	1.2%	< 0.001
Venous Stasis	0.9%	1.4%	< 0.001
Therapeutic Anticoagulation	2.2%	2.4%	0.172
Chronic Steroid Use	1.6%	1.4%	< 0.001
Smoking History	9%	9%	0.246
Prior Surgery	1.9%	1.7%	0.006
Need for Mobility Device	1.8%	2.4%	< 0.001

Patient Characteristic	LSG (n=93,062)	LRGYB (n=41,080)	P-value
Functional Status			< 0.001
Independent	99%	99%	
Partially dependent	0.6%	0.8%	
Totally dependent	0.4%	0.2%	
Level of Training of assistant			< 0.001
None	16%	12%	
PA/NP/RN	37%	39%	
Resident	17%	17%	
MIS Fellow	8%	12%	
Attending – Weight Loss Surgeon	16%	14%	
Attending - Other	6%	6%	
ASA Class			< 0.001
I	0.5%	0.2%	
II	26%	17%	
III	70%	78%	
IV	3.5%	4.6%	
V	0.01%	< 0.01%	

Random Forest Algorithm



Leak



Morbidity



Mortality



Unadjusted 30-day outcome	LSG	LRGYB	P-value
Leak	0.8%	1.6%	< 0.001
Morbidity	5.8%	11.7%	< 0.001
Mortality	0.1%	0.2%	< 0.001

Unadjusted 30-Day Outcomes

Complication	LSG (n=93,062)	LRGYB (n=41,080)	P-value
Urinary tract infection	0.31%	0.47%	< 0.001
Deep SSI	0.03%	0.20%	< 0.001
Organ space infection	0.29%	0.60%	< 0.001
Wound disruption	0.03%	0.1%	< 0.001
Sepsis	0.22%	0.61%	< 0.001
Renal failure	0.19%	0.38%	< 0.001
Bleeding requiring transfusion	0.57%	1.19%	< 0.001
Pneumonia	0.19%	0.51%	< 0.001
Venous thromboembolism	0.23%	0.23%	0.994
Pulmonary embolism	0.11%	0.15%	0.052
Myocardial infarction	0.03%	0.08%	0.001
Cardiac arrest	0.05%	0.09%	0.003
Cerebrovascular accident	0.01%	0.01%	0.526
Coma	0.01%	< 0.01%	0.137
Unplanned intubation	0.16%	0.40%	< 0.001
ICU admission	0.71%	1.65%	< 0.001
Ventilator greater than 48 hours	0.11%	0.39%	< 0.001
Intervention within 30 days	1.51%	3.33%	< 0.001
Reoperation within 30 days	1.22%	3.19%	< 0.001
Readmission within 30 days	4.05%	7.32%	< 0.001

Multivariate Model - Leak

Variable	OR	95% CI	P-value
LRYGB (compared to LSG)	2.10	1.88 – 2.34	< 0.001
Age (per year)	1.01	1.00 – 1.01	0.012
BMI (per kg/m ²)	1.01	1.00 – 1.02	0.001
Hyperlipidemia	0.82	0.71 – 0.94	0.004
Obstructive Sleep Apnea	1.22	1.09 – 1.37	0.001
Hypertension	1.20	1.06 – 1.36	0.004
Therapeutic Anticoagulation	1.82	1.39 – 2.39	< 0.001
Chronic Steroid Use	1.51	1.06 – 2.16	0.023
Need for Mobility Device	0.81	0.56 – 1.19	0.289
Functional Status (Compared to Independent)			
Partially dependent	2.52	1.62 – 3.91	< 0.001
Totally dependent	2.32	1.22 – 4.41	0.01
Level of training of assistant (compared to none)			
PA/NP/RN	1.16	0.97 – 1.40	0.101
Resident	1.06	0.86 – 1.35	0.573
MIS Fellow	0.80	0.62 – 1.04	0.100
Attending – Weight Loss Surgeon	0.81	0.65 – 1.02	0.075
Attending – Other	3.90	3.19 – 4.77	< 0.001
ASA Class (Compared to Class I)			
II	0.54	0.31 – 0.96	0.034
III	0.42	0.24 – 0.74	0.003
IV	0.37	0.20 – 0.69	0.002


Multivariate Model - Morbidity

Variable	OR	95% CI	P-value
LRGYB (compared LSG)	2.02	1.94 – 2.11	< 0.001
BMI (per kg/m²)	1.01	1.01 – 1.01	< 0.001
Albumin (per mg/dL)	0.80	0.75 – 0.84	< 0.001
Male (compared to Female)	0.91	0.86 – 0.96	< 0.001
Diabetes (compared to none)			
Non-insulin dependent	1.04	0.98 – 1.10	0.203
Insulin dependent	1.25	1.17 – 1.34	< 0.001
Hyperlipidemia	0.93	0.88 – 0.98	0.006
GERD	1.22	1.16 – 1.27	< 0.001
OSA	1.05	1.00 – 1.10	0.030
COPD	1.38	1.21 – 1.56	< 0.001
Oxygen dependence	1.47	1.23 – 1.76	< 0.001
Hypertension	1.17	1.12 – 1.22	< 0.001
History of MI	1.14	0.97 – 1.32	0.103
Prior Cardiac Surgery	1.54	1.32 – 1.79	< 0.001
Renal Insufficiency	1.67	1.38 – 2.02	< 0.001
Dialysis Dependence	1.69	1.26 – 2.27	0.001
History of PE	1.36	1.17 – 1.60	< 0.001
History of DVT	1.34	1.17 – 1.53	< 0.001
Prior IVC filter	1.76	1.51 – 2.05	< 0.001
Therapeutic Anticoagulation	1.64	1.46 – 1.84	< 0.001
Chronic Steroid Use	1.29	1.21 – 1.49	< 0.001
Smoking history	1.10	1.02 – 1.18	0.009
Prior Surgery	1.28	1.12 – 1.47	< 0.001
Need for Mobility Device	1.26	1.11 – 1.42	< 0.001
Functional Status (compared to Independent)			
Partially dependent	1.07	0.87 – 1.32	0.505
Totally dependent	1.50	1.13 – 2.00	0.005
Level of training of assistant (compared to none)			
PA/NP/RN	1.06	1.00 – 1.13	0.076
Resident	1.23	1.14 – 1.32	< 0.001
MIS Fellow	1.16	1.07 = 1.27	0.001
Attending – Weight Loss Surgeon	1.11	1.03 – 1.20	0.006
Attending - Other	1.38	1.26 – 1.52	< 0.001

Multivariate Model - Mortality

Variable	OR	95% CI	P-value
LRYGB (compared to LSG)	1.64	1.22 – 2.22	0.001
Age (per year)	1.04	1.03 – 1.06	< 0.001
BMI (per kg/m ²)	1.06	1.05 – 1.07	< 0.001
Male (compared to female)	2.22	1.63 – 3.01	< 0.001
Diabetes (compared to none)			
Non-insulin dependent	1.38	0.94 – 2.01	0.096
Insulin dependent	1.84	1.23 – 2.76	0.003
Hyperlipidemia	1.32	0.93 – 1.85	0.12
Oxygen dependence	2.65	1.43 – 4.91	0.002
Therapeutic Anticoagulation	3.13	2.04 – 4.82	< 0.001
Need for Mobility Device	1.69	1.00 – 2.88	0.051

Model Performance



Conclusions

- In the first 30 days, LSG was safer than LRYGB:
 - LSG had half the risk-adjusted odds of leak
 - LSG had half the risk-adjusted odds of morbidity
 - LSG had nearly half the risk-adjusted odds of death

- The reduced risk with LSG must be weighed against the benefits. Long term weight outcomes, metabolic disease resolution, and risk of GERD progression with LSG are still under study

- LSG is a better choice for high risk candidates.

Limitations

- Our study used a composite outcome of leak and morbidity.
- The discriminative ability of the models was poor for leak or morbidity.
- Outcomes after 30-days were not studied – delayed leak, stricture, ulcers, etc. are not included
- To really decide which procedure to recommend for a patient, better characterization of long-term results are needed: weight-loss maintenance, need for conversion, GERD, and diabetes resolution

Questions?